This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
The latest trading day saw Novartis (NVS) settling at $97.87, representing a -1.55% change from its previous close.
Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study
by Zacks Equity Research
Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous urticaria. The stock of the company rises 16%.
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B
by Zacks Equity Research
Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.
Novartis (NVS) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
Novartis (NVS) closed at $97.14 in the latest trading session, marking a +1.03% move from the prior day.
Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates
by Kinjel Shah
Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.
Novartis (NVS) Stock Moves -0.01%: What You Should Know
by Zacks Equity Research
The latest trading day saw Novartis (NVS) settling at $96.15, representing a -0.01% change from its previous close.
Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook
by Zacks Equity Research
Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio
by Zacks Equity Research
Eli Lilly's (LLY) acquisition of POINT Biopharma, if successfully closed, is likely to bolster its portfolio of cancer drugs.
Novartis (NVS) Announces Positive Data on Kidney Disease Drug
by Zacks Equity Research
Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novartis (NVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed the most recent trading day at $101.86, moving -0.46% from the previous trading session.
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
by Zacks Equity Research
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
by Zacks Equity Research
Pliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise
Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.
Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%
by Zacks Equity Research
Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.
Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar
by Zacks Equity Research
Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
by Zacks Equity Research
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
by Zacks Equity Research
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.
Novartis (NVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed the most recent trading day at $101.14, moving -0.93% from the previous trading session.
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
by Zacks Equity Research
Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
by Zacks Equity Research
The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
by Zacks Equity Research
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.